Results 61 to 70 of about 27,191 (241)
British Journal of Haematology, EarlyView.Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas +35 more
wiley +1 more source
A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen +5 more
wiley +1 more source
Diffuse osteolytic lesions in leukemic transformation of myelofibrosis [PDF]
Archive of Oncology, 2007 Myelofibrosis is a clonal myeloproliferative disorder characterized by splenomegaly, abnormal deposition of reticulin and collagen in the bone marrow, extramedullary hematopoiesis, dacryocytosis and leukoerythroblastic blood smear.
Jurišić Vladimir +3 more
doaj +1 more source
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala +14 more
wiley +1 more source
, 2010 Myelofibrosis is a reactive process common to many malignant and benign disorders. Primary myelofibrosis is a chronic myeloproliferative disorder of unknown aetiology that involves a multipotent haemopoietic progenitor cell and results in abnormalities ...
Jerry L. Spivak
core +1 more source
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system [PDF]
, 2019 Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or ...
Di Piazza, Florinda +13 more
core +1 more source
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Little is known about the correlation between subjective perception and objective measures of sleep quality in particular in the oldest‐old. The aim of this study was to perform longitudinal home sleep monitoring in this age group, and to correlate results with self‐reported sleep quality.
Hugo Saner +4 more
wiley +1 more source
Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung
Respiratory Medicine Case ReportsAlthough pulmonary complications are frequent in patients suffering from hematological diseases, secondary pulmonary alveolar proteinosis is a very rare complication of myelofibrosis.
Antoine El Kik +4 more
doaj +1 more source
Transfusion, EarlyView.Abstract Background Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance.
Karen Ziza +11 more
wiley +1 more source
Survival of patients with primary myelofibrosis.
, 2013 Patients were categorized according they were diagnosed with prefibrotic myelofibrosis, myelofibrosis-fibrotic type with early bone marrow fibrosis (grade 1) or myelofibrosis-fibrotic type with advanced bone marrow fibrosis (grade 2 or 3).
Paolo Catarsi (325689) +12 more
core +1 more source